Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines.
ROCKVILLE, Md. and NANTES, France, Feb. 4 /PRNewswire-FirstCall/ -- NOVAVAX and Vivalis (NYSE Euronext: VLS) announced today the completion of a research license to use the Vivalis proprietary EB66(R) cell line, for the production of Novavax VLP based vaccines. Through this collaboration, Novavax intends to test the EB66(R) cell...

Novel Vaccines Improve Potential for European Vaccines Manufacturers.
LONDON, Jan. 14 /PRNewswire/ -- The vaccines market, which was earlier associated with low profit margins and slow growth rates, has gained momentum in recent years through innovation. The introduction of novel vaccines for diseases with high burden and continuous investments aimed at boosting production capacity is driving the...

IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis.
SEATTLE, Jan. 22 /PRNewswire/ -- IDRI (Infectious Disease Research Institute) announced it has granted the Instituto Butantan, a Brazilian biomedical research institution, an exclusive license in Latin America and a non-exclusive license in the rest of the world to use two of IDRI's lead vaccine antigen candidates for the...

China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines.
DALIAN, China, Jan. 21 /PRNewswire-Asia-FirstCall/ -- China Bio-Immunity Corporation (BULLETIN BOARD: CHHB) (China Bio-Immunity" or "the Company"), a China-based company that develops, produces, manufactures and markets proprietary vaccine-based prophylactics and therapeutics exclusively within China, today announced that it has initiated a voluntary nationwide recall of the unused lots of...

Skipping vaccines is risky.
Byline: GUEST VIEWPOINT By Donna Givens The Register-Guard I appreciated the Jan. 10 article about vaccine resisters, an issue that I believe is of grave concern and in some circumstances is just plain frightening. As a family physician and the mother of a 2-year-old daughter, this issue...

Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study.
LYON, France, February 18 /PRNewswire-FirstCall/ -- - Global Clinical Study Program Across Dengue Endemic Regions in Latin America and Asia Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that its investigational tetravalent dengue vaccine is entering into a...

GeoVax to Present at the BIO CEO & Investor Conference 2009.
ATLANTA, Jan. 28 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (BULLETIN BOARD: GOVX) , an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., Chief Executive Officer and President, will present a corporate update...

Immune Targeting Systems Completes Second Tranche of Series-A Funding Bringing Total Funds Raised to More Than GBP5m.
Management Strengthened as Influenza Vaccine Prepares to Enter Clinic LONDON, January 28 /PRNewswire/ -- Immune Targeting Systems (ITS) Limited, a company developing synthetic vaccines for mutating viruses, today announced it has received GBP2.4m of investment as the second tranche of its series-A funding round. ITS's investors HealthCap,...

Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile.
Novel Vaccine Approach Tested in the UK Against One of the Most Common Causes of Hospital-Acquired Infection in Europe and North America LYON, France, February 17 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that it...

GeoVax Update Provided at the BIO CEO & Investor Conference 2009.
ATLANTA, Feb. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., Chief Executive Officer and President, presented a corporate update at...